Compare Gilead Sciences, Inc. (GILD) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Schwab US Large Cap Growth ETF — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while Schwab US Large Cap Growth ETF trades at $36.69 (market cap $65.01B). The key difference: Gilead Sciences, Inc. is far larger — about 2.8× Schwab US Large Cap Growth ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Schwab US Large Cap Growth ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Schwab US Large Cap Growth ETF for 50 Days on average.
| GILD | SCHG | |
|---|---|---|
Market Cap | $182.40B | $65.01B |
Volume | 4,469,821 | 8,554,399 |
Sector | Health | Sector/Thematic |
52-Week High | $155.80 | $36.93 |
52-Week Low | $116.74 | $28.10 |
Typical Hold Time | 111 Days | 50 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
SCHG trades at $36.87, down 0.16% with a bullish technical outlook from moving averages but bearish oscillators. The ETF maintains strong growth exposure with low expense ratios, though recent news highlights concentration risks in top holdings. Dividend activity remains minimal with a $0.04 distribution scheduled for September 2026.
Growth ETF positioning favors long-term investors despite near-term overbought signals. Key risks include heavy concentration in megacap tech stocks and potential valuation compression. Analyst sentiment remains positive for strategic allocations to large-cap growth exposure with disciplined entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
